Clinical trials: Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Ovarian Cancer, Epithelial Ovarian Cancer
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT02855944
- Testing
- Chemotherapy, Rucaparib
- Where
- 77 sites in United States, Brazil and 10 more
- Volunteers
- 349 people
- Sponsor
- pharmaand GmbH
Relapsed Ovarian Cancer
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
This study is a Phase II single-arm, open label, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma .
- Trial name
- NCT06081595
- Testing
- Fluzoparib, Apatinib
- Volunteers
- 54 people
- Sponsor
- Jin Li
PSR Ovarian Cancer With a BRCA Mutation
Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan
This is a single-arm, open label, expanded access program to provide access to olaparib tablets for relapsed high-grade epithelial ovarian cancer patients (including patients with primary peritoneal and / or fallopian tube…
- Trial name
- NCT03063710
- Testing
- olaparib
- Where
- 2 sites in Japan
- Sponsor
- AstraZeneca
Platinum-sensitive Relapsed Ovarian Cancer
Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer
The investigators explore the efficacy and safety of adebrelimab (PD-L1 inhibitor) plus chemotherapy and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib (PARP inhibitor)and…
- Trial name
- NCT06446206
- Testing
- Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib
- Volunteers
- 22 people
- Sponsor
- The First Hospital of Jilin University
Ovarian Cancer
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.
- Trial name
- NCT00849667
- Testing
- Farletuzumab, Carboplatin, Taxane
- Where
- 375 sites in United States, Argentina and 28 more
- Volunteers
- 1,100 people
- Sponsor
- Morphotek
Ovarian Cancer
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
To investigate the effectiveness and tolerability of a second maintenance treatment in participants with platinum-sensitivity relapsed (PSR) epithelial ovarian cancer, who have previously received PARPi maintenance treatment and…
- Trial name
- DUETTE (NCT04239014)
- Testing
- Olaparib, Ceralasertib
- Where
- 26 sites in United States, Canada and 2 more
- Sponsor
- AstraZeneca
Epithelial Ovarian Cancer
An Open Label Extension Study of the Efficacy of MORAb-003
An open label extension of the MORAb-003-002 study in order to continue the active patients in the MORAb-003-002 study on maintenance MORAb-003 infusions after the main study is closed.
- Trial name
- NCT01018563
- Testing
- MORAb-003
- Where
- 3 sites in United States, Germany
- Volunteers
- 3 people
- Sponsor
- Morphotek
Recurrent Ovarian Cancer
A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
The purpose of this study is to evaluate the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.
- Trial name
- NCT01851746
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wuhan University
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or…
- Trial name
- NCT02983799
- Testing
- OLAPARIB
- Where
- 47 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- AstraZeneca
Ovarian Cancer, Fallopian Tube Cancer
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
The purpose of this study is to evaluate the safety and efficacy of niraparib in Japanese participants with platinum-sensitive, relapsed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who achieved complete…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03759587
- Testing
- Niraparib
- Where
- 27 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Takeda
Ovarian Cancer
An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer
The purpose of this study is to assess the safety and efficacy of cediranib in combination with standard chemotherapy, in patients who have relapsed with ovarian, fallopian tube or epithelial cancer, after first line platinum…
- Trial name
- ICON6 (NCT00532194)
- Testing
- cediranib
- Where
- United Kingdom
- Volunteers
- 486 people
- Sponsor
- Medical Research Council
Non-Germline BRCA Mutated Ovarian Cancer
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients
The purpose of the study is to assess the efficacy and safety of single-agent olaparib as a maintenance treatment in patients with relapsed High Grade Serous Ovarian Cancer (including patients with primary peritoneal and/or…
- Trial name
- OPINION (NCT03402841)
- Testing
- Olaparib
- Where
- 91 sites in Austria, Belgium and 17 more
- Volunteers
- 279 people
- Sponsor
- AstraZeneca
Ovarian Cancer
Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer
Effect of biweekly schedule of PLD on dose-limiting toxicity of PPE and patient's quality of life
- Trial name
- NCT00170573
- Testing
- Caelyx
- Volunteers
- 77 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Fallopian Tube Cancer, Peritoneal Cavity Cancer
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and pegylated liposomal doxorubicin hydrochloride (PLD) work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Conditions
- Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT01281514
- Testing
- everolimus, carboplatin, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Ovarian Cancer
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
This phase I/II trial will determine the recommended dose and activity of BNC105P for patients with partially platinum sensitive ovarian cancer in first or second relapse.
- Trial name
- NCT01624493
- Testing
- Carboplatin, Gemcitabine, BNC105P
- Where
- 6 sites in United States, Australia and 1 more
- Sponsor
- Hoosier Cancer Research Network
Recurrent Ovarian Carcinoma
Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria
Various treatment options exist for patients with platinum-sensitive relapsed epithelial ovarian cancer (ROC). The register will provide an overview of chosen treatments including the reasons, why these options were chosen.
- Trial name
- NCT04369352
- Where
- 9 sites in Austria
- Volunteers
- 150 people
- Sponsor
- Medical University Innsbruck
Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, Platinum Sensitve Relapse
Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum
Patients with epithelial ovarian cancer, fallopian tube or peritoneal cancer who receive surgical cytoreduction and platinum/taxane containing chemotherapy have a significant chance of entering complete clinical remission but…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, Platinum Sensitve Relapse, Anemia
- Trial name
- NCT00189371
- Testing
- paclitaxel, carboplatin, epoetin alpha
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- AGO Study Group
Ovarian Cancer
Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
This is an open-label, single-arm, international, multicenter Multiple Patient Expanded Access Program (MPEAP). The program is designed to provide treatment access to olaparib tablets for patients with platinum-sensitive relapsed…
- Trial name
- NCT03079687
- Testing
- Olaparib tablets
- Where
- 13 sites in United States
- Sponsor
- AstraZeneca
Ovarian Epithelial Cancer Recurrent
A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer
A phase II single arm study of carboplatin and docetaxel in treatment of first sensitive relapse of epithelial ovarian, peritoneal or tubal cancer.
- Trial name
- NCT02026921
- Testing
- Carboplatin, Docetaxel
- Where
- 4 sites in Denmark, Finland and 1 more
- Volunteers
- 74 people
- Sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Ovarian Cancer, Neoplasms, Ovarian
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
This study was designed to find the most effective and safest doses of both HYCAMTIN and CARBOPLATIN that can be given for the treatment of ovarian cancer.
- Trial name
- NCT00316173
- Testing
- topotecan, CARBOPLATIN
- Where
- 22 sites in United States, Canada
- Volunteers
- 77 people
- Sponsor
- GlaxoSmithKline